NAVER D2SF, the corporate venture capital arm of South Korean internet giant NAVER, announced it has invested in ImpriMed, a Silicon Valley-based AI precision medicine company, participating in the startup's $10 million (approximately NT$320 million) Series A2 bridge financing round. ImpriMed's core technology combines ex vivo analysis of live patient-derived cancer cells with genomic, immunophenotypic, and clinical data, using multimodal AI models to support personalized treatment decisions, and its xCellSense platform can maintain patient cancer cells in a viable state outside the body for extended periods. ImpriMed is prioritizing blood cancers and bloodstream infections, with plans to obtain U.S. Food and Drug Administration (FDA) clearance and Clinical Laboratory Improvement Amendments (CLIA) certification by the first quarter of 2027. It has commercial partnerships with major U.S. medical institutions, including Mayo Clinic, and in South Korea developed prognostic and treatment response prediction software for multiple myeloma that received innovative medical device designation from South Korea's Ministry of Food and Drug Safety (MFDS). ImpriMed's expansion into human healthcare is backed by its veterinary oncology track record, having completed more than 27,000 canine and feline lymphoma tests, with a retrospective study showing a threefold improvement in patient survival time and a fourfold improvement in treatment response. Its services are integrated into more than 600 veterinary hospitals across the United States, Canada, the United Kingdom, France, and South Korea, and it has extended into drug